KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other financing activities: 2017-2025

Historic Other financing activities for Aquestive Therapeutics (AQST) over the last 4 years, with Sep 2025 value amounting to $7,000.

  • Aquestive Therapeutics' Other financing activities fell 12.50% to $7,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3,000, marking a year-over-year increase of 100.04%. This contributed to the annual value of $4.6 million for FY2023, which is N/A change from last year.
  • Aquestive Therapeutics' Other financing activities amounted to $7,000 in Q3 2025, which was down 12.50% from $8,000 recorded in Q2 2025.
  • Aquestive Therapeutics' Other financing activities' 5-year high stood at $9.1 million during Q1 2023, with a 5-year trough of -$7.9 million in Q4 2023.
  • Moreover, its 3-year median value for Other financing activities was $6,000 (2025), whereas its average is $424,000.
  • The largest annual percentage gain for Aquestive Therapeutics' Other financing activities in the last 5 years was 99.77% (2024), contrasted with its biggest fall of 99.94% (2024).
  • Quarterly analysis of 3 years shows Aquestive Therapeutics' Other financing activities stood at -$7.9 million in 2023, then soared by 99.77% to -$18,000 in 2024, then declined by 12.50% to $7,000 in 2025.
  • Its Other financing activities stands at $7,000 for Q3 2025, versus $8,000 for Q2 2025 and $6,000 for Q1 2025.